- Market Capitalization, $K 589,971
- Shares Outstanding, K 88,319
- Annual Sales, $ 143,010 K
- Annual Income, $ -400,420 K
- 60-Month Beta 2.10
- Price/Sales 3.07
- Price/Cash Flow N/A
- Price/Book N/A
|Period||Period Low||Period High||Performance|
| || |
+1.66 (+33.07%)since 12/22/20
| || |
+1.05 (+18.76%)since 10/22/20
| || |
-2.46 (-26.91%)since 01/22/20
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, 2020. The financial information presented...
Clovis (CLVS) submits regulatory application to the FDA for initiating clinical study on its peptide-targeted radionuclide therapy, FAP-2286.
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the company has completed submission of two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for FAP-2286,...
Clovis Oncology (NASDAQ:CLVS) traded in a range yesterday that spanned from a low of $4.82 to a high of $4.93. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $4.86...
Companies in the news are: LESL, RP, AJRD, CLVS
Clovis' (CLVS) Rubraca achieves significant improvement in progression free survival compared to chemotherapy in late-stage confirmatory study for BRCA-mutated ovarian cancer indication.
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGIO, CLVS, AQMS, COCP, and LAZR.
Clovis Oncology, Inc. (NASDAQ: CLVS), today announced topline data from the randomized Phase 3 ARIEL4 study of Rubraca, which met its primary endpoint of improved investigator-assessed progression-free...
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
, /PRNewswire-PRWeb/ -- Alucio™, a fast-growing provider of cloud-based software for the life sciences industry, today announced that Clovis Oncology has selected Alucio's Beacon as its scientific...